Edgewise Therapeutics, Inc.

EWTX Nasdaq SEC CIK 1710072
Follow Edgewise Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income $1.2B +2967.6% vs same quarter last year
EPS, diluted $9.65 +2574.4% vs same quarter last year
Operating cash flow −$78.3M −125.1% vs same quarter last year
Operating income −$46.1M +1.5% vs same quarter last year
Net income by quarter
$94M
−$40.8M
−$36.1M
−$40.7M
$117.4M
−$49M
−$57.3M
$1.2B
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$80M−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$167.8K
FY24−$133.8K
FY23−$100.2K
FY22−$67.6M
FY21−$42.8M
FY20−$17.1M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$144.1M
FY24−$110.3M
FY23−$97.7M
FY22−$58.2M
FY21−$34.2M
FY20−$14.8M
FY19-